Komrokji Rami S, Bennett John M
James P Wilmot Cancer Center, Strong Memorial Hospital, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.
Curr Hematol Rep. 2005 May;4(3):175-81.
Myelodysplastic syndromes (MDS) are a heterogeneous group of neoplastic clonal stem cell diseases characterized by dysplastic morphological features with a varying percentage of leukemic blasts and clinical bone marrow failure. The French-American-British (FAB) system served as the gold standard of MDS classification for more than two decades. The World Health Organization (WHO) classification, built on the backbone of the FAB classification, is an attempt to further improve the prognostic value of MDS classification as well as to establish its clinical utility as a tool to select different treatments. In this article we highlight the major differences between the FAB classification and the WHO MDS classification. We discuss in more details the experience of using the new WHO classification since its publications and review the studies that tried to either validate the prognostic value of the new classification or apply it to predict clinical responses to various treatments.
骨髓增生异常综合征（MDS）是一组异质性的肿瘤性克隆性干细胞疾病，其特征为发育异常的形态学特征、不同比例的白血病原始细胞以及临床骨髓衰竭。法美英（FAB）系统作为MDS分类的金标准已有二十多年。世界卫生组织（WHO）分类以FAB分类为基础，旨在进一步提高MDS分类的预后价值，并确立其作为选择不同治疗方法工具的临床实用性。在本文中，我们重点介绍FAB分类与WHO MDS分类之间的主要差异。我们更详细地讨论自WHO新分类发布以来使用该分类的经验，并回顾那些试图验证新分类的预后价值或应用其预测各种治疗临床反应的研究。
